These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37835810)

  • 1. Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer.
    Mori K; Matsumoto K; Ikeda M; Koguchi D; Shimizu Y; Tsumura H; Ishii D; Tsuji S; Sato Y; Iwamura M
    Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer.
    Mori K; Matsumoto K; Amano N; Koguchi D; Shimura S; Hagiwara M; Shimizu Y; Ikeda M; Sato Y; Iwamura M
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of previous tonsillectomy after radical cystectomy for bladder cancer.
    Gakis G; Hassan FN; Schmid MA; Ölschläger M; Hackenberg S; Stenzl A; Renninger M
    Scand J Urol; 2020 Aug; 54(4):297-303. PubMed ID: 32500778
    [No Abstract]   [Full Text] [Related]  

  • 4. HEG1 as a novel potential biomarker for the prognosis of lung adenocarcinoma.
    Zou X; Zhang Y; Wang N; Shi J; Li Q; Hao W; Zhu W; Han W
    Cancer Med; 2023 Feb; 12(3):3288-3298. PubMed ID: 35950222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
    Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
    Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
    Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
    Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of tumor-associated immune cell infiltrates at radical cystectomy for bladder cancer.
    Schubert T; Renninger M; Schmid MA; Hassan FN; Sokolakis I; Fahmy O; Hatzichristodoulou G; Stenzl A; Gakis G
    Urol Oncol; 2020 Jan; 38(1):4.e7-4.e15. PubMed ID: 31537484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas.
    Hiroshima K; Wu D; Koh E; Sekine Y; Ozaki D; Yusa T; Nakazawa T; Tsuji S; Miyagi Y; Walts AE; Marchevsky AM; Husain AN; Imai K
    Pathol Int; 2021 Sep; 71(9):604-613. PubMed ID: 34240508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy.
    Ha YS; Kim SW; Chun SY; Chung JW; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Kim WT; Kim WJ; Kim TH
    BMC Urol; 2019 Jan; 19(1):10. PubMed ID: 30678673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell invasion in blood vessels assessed by immunohistochemistry is related to decreased survival in patients with bladder cancer treated with radical cystectomy.
    Carlsen B; Klingen TA; Andreassen BK; Haug ES
    Diagn Pathol; 2021 Nov; 16(1):109. PubMed ID: 34809660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
    Janisch F; D'Andrea D; Iwata T; Kimura S; Abufaraj M; Enikeev D; Glybochko PV; Karakiewicz PI; Nyirady P; Fajkovic H; Haitel A; Seebacher V; Rink M; Shariat SF
    Urol Oncol; 2020 May; 38(5):423-432. PubMed ID: 32209281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bladder cancer variant histology on survival outcome in patients treated with radical cystectomy: A single-centre experience.
    Komina S; Petrusevska G; Janevska V; Jovanovic R; Zdravkovski P; Saidi S; Zafirovska BI; Topuzovska S
    Urol Ann; 2021; 13(3):288-295. PubMed ID: 34421267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
    Mertens LS; Claps F; Mayr R; Bostrom PJ; Shariat SF; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; Peters D; van der Heijden MS; Jewett MAS; Stöhr R; Zlotta AR; Eckstein M; Soorojebally Y; van der Schoot DKE; Wullich B; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; van der Kwast TH; Hartmann A; Lotan Y; Allory Y; Zuiverloon TCM; van Rhijn BWG
    Urol Oncol; 2022 Mar; 40(3):110.e1-110.e9. PubMed ID: 34906411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
    Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline Health-related Quality of Life Predicts Bladder Cancer-specific Survival Following Radical Cystectomy.
    Westhofen T; Eismann L; Buchner A; Schlenker B; Giessen-Jung C; Becker A; Stief CG; Kretschmer A
    Eur Urol Focus; 2022 Nov; 8(6):1659-1665. PubMed ID: 35184991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy.
    Morizawa Y; Miyake M; Shimada K; Hori S; Tatsumi Y; Nakai Y; Anai S; Tanaka N; Konishi N; Fujimoto K
    Urol Oncol; 2016 Jun; 34(6):257.e11-7. PubMed ID: 27038696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy.
    Gakis G; Ngamsri T; Rausch S; Mischinger J; Todenhöfer T; Schwentner C; Schmid MA; Hassan FA; Renninger M; Stenzl A
    World J Urol; 2015 Oct; 33(10):1429-37. PubMed ID: 25595732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy.
    Koguchi D; Matsumoto K; Shimizu Y; Kobayashi M; Hirano S; Ikeda M; Sato Y; Iwamura M
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of the systemic immune-inflammation index for patients with bladder cancer after radical cystectomy.
    Zhang S; Du J; Zhong X; Tan P; Xu H; Zhang J; Jin D; Li Y; Le W; Xiong X; Lin T; Wei Q
    Front Immunol; 2022; 13():1072433. PubMed ID: 36524107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.